Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Moderna

Moderna’s mRNA vaccines to be exempt from advisory committee scrutiny under $2bn Morrison-era deal

Exclusive: Critics say exemption ‘deeply concerning’ and risks creating separate assessment systems

The Guardian - AU

New vaccine facility a shot in the arm for Australians

Up to 100 million mRNA jabs will be made at Moderna's new plant, with a promise Australia will always be at the top of the vaccine queue for locally-made jabs.

AAP

2 Vaccine Stocks to Buy on the Dip

Given the cutting-edge pipeline for these two vaccine companies, double-digit slumps in these stocks present a compelling entry point for investors.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Biotech’s Bull Run Over? Examining Election Impacts

The biotech sector's breakout attempt post-election reversed sharply, with ETFs like IBB and XBI falling and invalidating the long-term bullish setup.

MarketBeat

Deciphering Disruption: Inside Cathie Wood's Latest Plays

Cathie Wood's recent stock market activity offers a glimpse into her evolving investment strategy and the potential of disruptive technologies.

MarketBeat

Stocks Settle Sharply Lower on the Outlook for Slower Fed Rate Cuts

The S&P 500 Index ($SPX ) (SPY ) Friday closed down -1.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.40%. Stocks retreated Friday, with the S&P 500 and Nasdaq 100 falling to 1-1/2 week...

Barchart

Stocks Tumble as Hawkish Fed and Strong US Economic News Boosts Bond Yields

The S&P 500 Index ($SPX ) (SPY ) today is down -1.17%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.72%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.03%. Stocks today extended Thursday’s decline, with the S&P 500 and the Dow Jones Industrials...

Barchart

Read news from The Economist, FT, and more,
with one subscription

Pharma shares hit as Trump picks RFK Jr to lead health department

Choice of vaccine critic knocks some of world’s biggest drugmakers including Moderna, AstraZeneca and GSK

The Guardian - UK

Moderna Stock Outlook: Is Wall Street Bullish or Bearish?

Moderna has underperformed the broader market and its peers over the past year, and Wall Street analysts are cautious about the stock’s prospects.

Barchart

Don't wait for a holiday surge. Now is a good time to get your flu and COVID-19 vaccines

Health officials say it's important to get flu and COVID-19 vaccines ahead of the holidays when respiratory bugs tend to spread

The Independent UK

Option Volatility And Earnings Report For November 4 - 8

We have some important companies with Palantir, Super Micro computer, Block, Moderna, Qualcomm, Arista Networks, Gilead Sciences and Airbnb all set to report.

Barchart

Older adults should get 2 doses of the updated COVID shot, CDC says

The 2024-2025 COVID-19 vaccines are available, and the CDC recommends that certain groups get two doses, spaced six months apart.

LiveScience

Norovirus vaccine: How does the trial work, when could it be available and what will it mean for the NHS?

Could the new ‘winter vomiting bug’ vaccine save the NHS in future winters?

The Independent UK

Doctors trial world’s first mRNA vaccine against vomiting bug norovirus

Jab could bring huge health and economic benefits as virus often spreads very rapidly and can be serious

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

World-first vaccine for vomiting bug norovirus trialled in the UK

The jab uses mRNA technology to tell the immune system to recognise a ‘foreign’ protein on viruses and mount an attack.

The Independent UK

World’s first vaccine for winter vomiting bug norovirus to be trialled in UK

Final phase of vaccine trial to start soon using the same technology as Covid-19 jabs

Barchart

Earnings Preview: What to Expect From Moderna's Report

Moderna is all set to release its fiscal third-quarter earnings next month, and analysts project its loss to rise in double digits.

The Conversation

One of science’s greatest achievements: how the rapid development of COVID vaccines prepares us for future pandemics

Since COVID was first reported in December 2019, there have been more than 775 million recorded infections and more than 7 million deaths from the disease. This makes COVID the seventh-deadliest pandemic in recorded history.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

It's time to roll up sleeves for new COVID, flu shots

Fall means it’s time for just about everybody to get up to date on their flu and COVID-19 vaccines

Fortune

Will the XEC COVID subvariant bring a fall wave of infections? What to know about symptoms and spread

The U.S. is coming down from its biggest COVID summer surge yet as a new subvariant emerges—but new vaccines are here, too.

The Independent UK

Cancer vaccine breakthrough as tests show positive results on patients with tumours

The jab, known as mRNA-4359, is developed by Moderna

Kiplinger

Stock Market Today: Stocks Rise in Choppy Day for Markets

Moderna was the worst S&P 500 stock today after the vaccine maker slashed its R&D budget.

Kiplinger

Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know

Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.

Barchart

Is Moderna Stock Underperforming the Nasdaq?

While Moderna has underperformed the broader Nasdaq index in 2024, analysts are reasonably bullish about the stock's potential.

Barchart

Stocks Finish Higher on Support From Chip Stock Rebound

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +1.16%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.30%. Stocks on Monday posted moderate gains on some dip buying following last Friday’s sharp...

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.